Also note that the battle of insurance coverage of the drug is raging -- many do not pay retail for the drug, and Wegovy improving heart conditions opens up another path to needing to be covered by insurers.

On the fringes, I read (can't remember where) that some other large pharmas in the US are working on their own formulations that trigger GLP1, and abroad India and China have taken an interest (there are quite a few Chinese research papers floating around on the effects).